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I
n the United States, there are currently 
about 400 000 patients with end-stage 
renal disease (ESRD), and about 19 mil-
lion individuals have chronic kidney dis-
ease.1 In 1973, as a result of the Social Security 
Amendments of 1972 (Public Law 92-603, sec-
tion 299I), the Medicare ESRD Program was 
established, which covers dialysis and kidney 
transplantation. In the 30 years since its incep-
tion, the Medicare ESRD Program has provided 
life-saving dialysis treatments and transplants to 
over one million people and has been regarded 
as an unqualifi ed success.
However, there are several limitations to this 
program, and one major issue has been pre-
scription coverage. Because of their high cost, 
only two categories of outpatient prescription 
drugs are currently covered under the Medicare 
ESRD Program (Part B): immunosuppressant 
(anti-rejection) drugs for kidney transplant 
patients, and erythropoietin, which is used 
to treat anemia in dialysis patients.2 Th ere are 
several facets to the problems of prescription 
coverage in kidney failure patients. 
(1)  Th e transplant recipient with Medicare and 
without any secondary insurance must pay 
20% of the cost of anti-rejection medications 
not covered by Medicare, which amounts to 
approximately US$300–$400 per month (in 
addition to the cost of other medications he 
or she must take, which may raise the total 
to $1000–$3000 per month3). ESRD patients 
consume more medications (the mean number 
of medications ranges from seven to ten) than 
other Medicare benefi ciaries because of their 
multiple comorbidities. It has been shown 
that those patients with at least one secondary 
payer use more medications, and the number 
of medications prescribed also increases as 
the number of secondary insurance carriers 
increases.4 Th is implies that not possessing 
prescription coverage leads to a decrease in 
consumption of medications that would be 
necessary to optimize the health of dialysis 
and transplant patients.
(2)  Another important issue is that the termina-
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sant coverage aft er three years jeopardizes 
the health of patients who have received 
transplants and do not have other insurance 
to cover drug costs. Ironically, if the patient’s 
graft  fails as a result of inability to pay for 
immunosuppressants, the return to mainte-
nance dialysis makes the patient again eligible 
for Medicare through the ESRD program.4 
Moreover, although newer immunosup-
pressive drugs tend to be more eff ective in 
reducing the risk of acute rejection, they are 
also more expensive. Th us, when transplant 
recipients lose prescription drug coverage, it 
becomes even more fi nancially burdensome 
to pay for their maintenance immunosup-
pression. It has been shown that optimal 
medication adherence can be obtained when 
recipients are provided with guidance in 
securing their necessary medications without 
fi nancial restriction.5
(3)  ESRD patients have been prohibited by sec-
tion 1876 of the Social Security Act from 
joining managed care organizations, unless 
they are already enrolled in one before start-
ing dialysis or receiving a kidney transplant. 
Although this legislation was passed to 
address managed care organizations’ con-
cerns regarding the expense of ESRD enroll-
ees, it remains in place because of concern 
over the potential incentives under managed 
care to undertreat patients with a chronic dis-
ease. ESRD patients may benefi t from join-
ing managed care organizations for several 
reasons (for example, these patients are best 
served by providers who are experienced 
in several unique aspects of their care), and 
barring them from such organizations may 
deny prescription and other health coverage 
to eligible patients.
(4)  Lastly, the rapid growth in the population 
of ESRD patients has led to an escalation in 
costs; in 2002, ESRD costs averaged $16.2 bil-
lion, and even though ESRD patients made up 
only 0.8% of Medicare enrollment, over 6.7% 
of Medicare expenses were for ESRD.6 Several 
factors account for this increase in expendi-
ture, including increases in enrollment and 
in the numbers of older and diabetic patients 
(these factors alone have increased expendi-
tures by 21%).
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Medicare Prescription Drug, Improvement, and Modernization 
Act (Part D) and the ESRD patient
As a prelude to the Part D program, on March 25, 2004, prescrip-
tion drug discount card programs were endorsed by the secretary of 
health and human services. It was estimated that these drug discount 
card programs would enable two million Medicare benefi ciaries to 
save 15%–25% on their prescriptions, beginning June 1, 2004. On 
December 8, 2003, the Medicare Prescription Drug, Improvement, 
and Modernization Act (Public Law 108-173) was signed into law. 
Th e legislation may provide enhanced benefi ts for many kidney 
patients, especially those who previously had no insurance to pay 
for oral prescription medications. Th e drug insurance program, 
which is voluntary and is available under a new Part D of Medicare, 
became eff ective on January 1, 2006, replacing the drug discount 
card program. Anyone entitled to Medicare Part A or enrolled in 
Medicare Part B is eligible for Part D benefi ts. Most prescription 
drugs are on the Part D plan formulary, which must include at 
least two drugs in a given category or class of the most commonly 
prescribed drugs. Formularies include generics and brand-name 
drugs. Th e Centers for Medicare and Medicaid Services (CMS), 
which run Medicare, have approved ten national prescription drug 
plan organizations and hundreds of state or regional stand-alone 
prescription drug plan organizations. In addition, new Medicare 
Advantage plans, which are health maintenance organizations, also 
off er drug coverage as part of their standard benefi t packages.
Th e fi rst $250 in drug expenses each year is the responsibility of 
the benefi ciary (‘deductible’). Th e benefi ciary bears 25% of drug 
expenditures between $250 and $2250 per year (‘copayment’). 
Ninety-fi ve percent of the cost of medications (‘catastrophic’ benefi t) 
is covered aft er the benefi ciary has spent $3600 out of pocket ($5100 
in total drug costs). Th is gap in coverage — benefi ciaries must bear 
100% of drug expenses between $2250 per year and $3600 per year 
— has been described as the ‘doughnut hole.’ Th ere is graduated 
relief from the deductible and copayment requirements (as well 
as the ‘doughnut hole’) for benefi ciaries with income below 150%, 
135%, and 100% of the poverty level. Th ere are also asset restrictions 
on this relief. For Medicare benefi ciaries whose income is above 
150% of the poverty level, it is estimated that, on average, Medicare 
Part D will cover half the cost of their prescriptions.7 
Th e Part D program is a potentially signifi cant development for 
ESRD patients. Th ere can be considerable cost savings to patients 
who are on multiple medications (as the average ESRD patient 
routinely spends more than $5100 in drug costs). Th e biggest 
disadvantage for ESRD patients is that the statute specifi es that 
drugs covered under Part B cannot be reimbursed under Part D. 
Th us Medicare still covers expensive anti-rejection drugs at the 
80% rate for three years, and additional coverage is not available 
under Part D aft er this period. Th ere are also concerns about the 
cost containment measures: the establishment of formularies may 
produce unique problems for ESRD patients. Specifi c medications 
that ESRD patients need may not be in formularies. Also, the need 
for prior authorization to switch from brand name to generic and 
from generic to generic is potentially dangerous (especially to 
transplant patients, who need very tightly regulated drug levels).8 
Dually eligible patients (those possessing Medicare and Medicaid) 
who have incomes above 150% of the poverty level may have more 
out-of-pocket expenses for medications, because their prescription 
drugs are now covered under Medicare Part D rather than their 
state Medicaid program. Medicare Part D has higher deductibles 
and requires larger copayments than are typical for Medicaid pro-
grams. Low-income Americans, when they enroll in Part D, may 
lose access to the free medications that drug manufacturers some-
times provide; the eligibility requirements of industry-sponsored 
pharmaceutical assistance programs typically exclude individuals 
who have Medicare coverage.
Conclusion
Th e Medicare ESRD Program has been remarkably successful in 
maintaining the lives of several hundred thousand kidney failure 
patients. However, a signifi cant number of these patients cannot 
aff ord the cost of prescription medications that are not covered by 
Medicare or that have high copayment rates. Medicare Part D pro-
vides the best opportunity for covering Medicare ESRD patients. 
By providing comprehensive prescription coverage, it is likely to 
reduce noncompliance due to fi nancial reasons and to improve 
outcome and mortality. However, the current model requires 
several modifi cations tailored to the needs of this population. A 
special formulary committee should be set up to oversee the spe-
cial needs of ESRD patients. Separate categories in the formularies 
should be included for transplant medications and chronic kidney 
disease medications. Lumping these medications together with 
other classes may reduce choices of essential medications. National 
not-for-profi t organizations (such as the National Kidney Founda-
tion) that serve the needs of ESRD patients should be allowed to 
work closely with the policy makers in this program. Immunosup-
pressive medication coverage should be moved from Part B to Part 
D. Th is would reduce out-of-pocket payments for this expensive 
group of medications. Th e 36-month-expiration rule should be 
removed for transplant immunosuppressive medications, which 
should be covered by the plan indefi nitely. Although there would 
be cost increases associated with any and all of the above, it is 
unlikely that they would involve a major proportion of the $400 
billion earmarked for the Medicare Part D program, given the rela-
tively small number of ESRD patients. Kidney transplant patients 
may see longer transplant survival times, and dialysis patients may 
actually see better control of their comorbid conditions, which may 
off set the increase in costs.
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